Bio-Techne reports Q3 adjusted EPS 53c, consensus 53c

Reports Q3 revenue $294.15M, consensus $296.66M. "Our third quarter performance was consistent with our expectations, as we continue to lap high growth rates from the prior year, China continued to recover from Covid-related restrictions, and biotech funding considerations impacted a subset of our biopharma customers," said Chuck Kummeth, president and CEO of Bio-Techne. "The team continued to effectively execute our strategy across the organization, enabling a 150 basis point sequential adjusted operating margin expansion to 37.0%."